Lecanemab Data On Benefit In Alzheimer’s Might Satisfy FDA – But What About Medicare?

 
• By Cathy Kelly
CMS Will Face Significant Pressure To Allow Broader Access To Lecanemab • Source: Shutterstock

More from Market Access

More from Pink Sheet